Quantcast
Last updated on April 18, 2014 at 10:39 EDT

Latest Edison Pharmaceuticals Inc. Stories

2014-03-10 00:21:49

First subject enrolled in pivotal clinical trial MOUNTAIN VIEW, Calif., March 10, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B/3 study entitled, "A Phase 2B/3 Open-label Study of EPI-743 in Children with Leigh Syndrome" to be conducted in conjunction with Dainippon Sumitomo Pharma Co, Ltd. The trial is an open-label study lasting six months. To be eligible for the trial, children must have clinical and radiographic evidence of Leigh...

2014-02-04 23:27:41

MitoAction and UMDF have joined together to congratulate Edison Pharmaceuticals in their announcement last week of a nearly $4.3 billion strategic partnership with Dainippon Sumitomo Pharma Co., Ltd. of Japan. (PRWEB) February 04, 2014 The nation’s leading mitochondrial disease patient advocacy organizations have joined together to congratulate Edison Pharmaceuticals in their announcement last week of a nearly $4.3 billion strategic partnership with Dainippon Sumitomo Pharma Co., Ltd....

2014-02-04 00:21:05

EPI-743 in phase 2 development for Friedreich's ataxia MOUNTAIN VIEW, Calif., Feb. 4, 2014 /PRNewswire/ -- Edison Pharmaceuticals today announced that the US Food and Drug Administration has granted Orphan Status to vatiquinone for the treatment of Friedreich's ataxia. Vatiquinone is the International Nonproprietary Name (INN) for Edison's EPI-743. The INN is a unique international name issued by the World Health Organization. It is used to identify the active pharmacological...

2013-03-28 08:29:16

MOUNTAIN VIEW, Calif., March 28, 2013 /PRNewswire/ -- Edison Pharmaceuticals today announced that it has entered into a research/development and commercialization agreement with Dainippon Sumitomo Pharma Co., Ltd. (DSP) for the development of EPI-743 and EPI-589 in Japan. Under the terms of the agreement, DSP will gain development and commercialization rights in Japan in exchange for Edison receiving $35 million in upfront and $15 million in R&D support. In addition, Edison will...

2013-02-19 00:21:28

MOUNTAIN VIEW, Calif., Feb. 19, 2013 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2 clinical trial entitled, "Double-Blind, Placebo-Controlled Clinical Trial of EPI-743 in Patients with Cobalamin C Defect." The trial is a placebo-controlled study lasting 12 months, preceded by a six-month run-in phase for all patients to establish a defined clinical and metabolic baseline. The primary endpoint is improvement in visual function with secondary outcome...

2013-01-07 00:20:46

MOUNTAIN VIEW, Calif., Jan. 7, 2013 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "Safety and Efficacy Study of EPI-743 on Visual Function in Patients with Friedreich's Ataxia." The trial is a placebo-controlled study lasting six months, followed by an extension phase in which all subjects will receive EPI-743. Subjects must be between 18 and 45 years of age, possess genetic confirmation of Friedreich's ataxia, and meet...

2012-11-26 12:29:20

MOUNTAIN VIEW, Calif., Nov. 26, 2012 /PRNewswire/ -- Edison Pharmaceuticals, Inc. announced today that it has closed a Series F Preferred Financing, raising $20M. Mitsui & Co. Global Investment, Inc. led the financing and will occupy a board of directors seat. Proceeds will be used to advance the clinical development of EPI-743. The company has recently announced the initiation of phase 2B clinical trials in the United States in two orphan mitochondrial diseases, Leigh syndrome and...

2011-09-13 10:56:00

MOUNTAIN VIEW, Calif., Sept. 13, 2011 /PRNewswire/ -- Edison Pharmaceuticals, Inc. announced today that it has closed a Series E Preferred Financing. Capital raised will fund US and European approval trials for the company's clinical candidates, EPI-A0001 and EPI-743. Terms of the financing were not disclosed. Edison Pharmaceuticals Edison Pharmaceuticals is a patient- and physician-founded company devoted to developing new medicines to transform the lives of children and adults...

2011-06-10 16:38:00

MOUNTAIN VIEW, Calif., June 10, 2011 /PRNewswire/ -- Edison Pharmaceuticals, Inc. announced today preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich's ataxia. While the primary endpoint of glucose disposition index (a measure of glucose handling by the body) did not show statistically significant improvement, EPI-A0001 did significantly improve neurological function as assessed by the Friedreich's Ataxia Rating Scale (FARS). This double-blind placebo-controlled...

2011-06-08 02:01:00

MOUNTAIN VIEW, Calif., June 8, 2011 /PRNewswire/ -- Edison Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has allowed an Expanded Access program to provide EPI-743 to seriously ill patients diagnosed with inherited respiratory chain diseases of the mitochondria. Patients with genetically confirmed disease and patients who meet specific clinical criteria, absent genetic confirmation are both eligible. As of June 1, 2011, 40 seriously ill subjects...